ESR1 and breast cancer: On the other hand, multiple studies have demonstrated the improved prognosis of PR+ breast cancers [74,75,76,77,78,79], and a Combined Endocrine Receptor (CER) score averaging the Allred score of both ER and PR has been demonstrated to be a more powerful discriminator of patient outcome than either ER or PR alone [80].